CN107412282A - Application of the HEIHUZHANG fungus extract in antiprostate cancer, health products or food is prepared - Google Patents
Application of the HEIHUZHANG fungus extract in antiprostate cancer, health products or food is prepared Download PDFInfo
- Publication number
- CN107412282A CN107412282A CN201710352457.2A CN201710352457A CN107412282A CN 107412282 A CN107412282 A CN 107412282A CN 201710352457 A CN201710352457 A CN 201710352457A CN 107412282 A CN107412282 A CN 107412282A
- Authority
- CN
- China
- Prior art keywords
- heihuzhang fungus
- extract
- heihuzhang
- food
- health products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000233866 Fungi Species 0.000 title claims abstract description 60
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 32
- 239000000284 extract Substances 0.000 title claims abstract description 27
- 201000011510 cancer Diseases 0.000 title claims abstract description 16
- 230000036541 health Effects 0.000 title claims abstract description 12
- 235000013305 food Nutrition 0.000 title claims abstract description 11
- 239000002026 chloroform extract Substances 0.000 claims description 27
- 239000000843 powder Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 150000002170 ethers Chemical class 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000569924 Pinanga maculata Species 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 abstract description 20
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 14
- 238000011580 nude mouse model Methods 0.000 abstract description 11
- 241000699660 Mus musculus Species 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000012010 growth Effects 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 4
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 abstract description 2
- 238000011047 acute toxicity test Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 21
- 238000001514 detection method Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 2
- 229960005314 suramin Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 241000409065 Albatrellus dispansus Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000577937 Sarcodon imbricatus Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 244000273618 Sphenoclea zeylanica Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000037111 immune power Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 210000000064 prostate epithelial cell Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of the HEIHUZHANG fungus extract in antiprostate cancer, health products or food is prepared.The present invention through vitro prostate cancer cells experimental studies have found that, HEIHUZHANG fungus extract can significantly inhibit the growth of prostate gland cancer cell LNCaP, 22Rv1, PC 3 and the grades of DU 145.Interior animal experiment research simultaneously finds that HEIHUZHANG fungus extract can significantly inhibit the growth of prostate gland cancer cell LNCaP transplanted tumor in nude mice；Confirm that its safe-dosaging limits is larger, available for fields such as antiprostate cancer, health products or food through cell acute toxicity test.
Description
Technical field
The present invention relates to the new application of HEIHUZHANG fungus extract, and in particular to HEIHUZHANG fungus extract is preparing anti-prostate
Application in cancer drug, health products or food.
Background technology
According to the latest data of National Cancer Center, prostate cancer from 2008 as urinary system in incidence of disease highest
Tumour, the incidence of disease of 2009 reaches 9.92/10 ten thousand, the 6th arranged in male malignancy incidence of disease ranking；The death rate reaches
To 4.19/10 ten thousand, the 9th is arranged in all male malignancies.Therefore, the preventing and treating of prostate cancer has become tumour in China
One significant challenge in field.
The treatment method of prostate cancer is a lot, including follow-up observation, transurethral prostatic resection（Transurethral
Resection of Prostate, TURP）, it is radical-ability prostate excision, radiotherapy, cold therapy, endocrine therapy, comprehensive
Close treatment etc..Hormone Withdrawal removes therapy (reducing hormone in vivo level by orchiectomy or using antiandrogen etc.) still
It is the prefered method of current treatment prostate cancer.Clinical conventional chemotherapeutic has at present:Docetaxel (DocetaxeD, meter Fei
Department's ketone (Mifepristone), suramin (Suramin), ketone health frustrate (Ketoconazole), rice support green onion quinone
(Mitoxantrone) etc..Systemic chemotherapy based on Docetaxel be uniquely be proved can proper extension HRPC patient life
Deposit the medicine of phase.But about 50% advanced prostate cancer patients are insensitive to Docetaxel treatment, or even produce obvious
Toxic reaction.Antineoplastic developing focus has shifted towards natural plant and its main monomer component, and traditional Chinese medical science medicinal plants are anti-swollen
Knurl effect is verified effectively by Clinical practice all the time.
HEIHUZHANG fungus flat property and sweet taste, there is wind-evil dispelling and cold-evil expelling, relaxing tendons and activating collaterals, heat-clearing, anti-inflammatory, degerming, courage can be reduced and consolidated
Alcohol, enhance metabolism, improve body immunity, being the high tonic of person in poor health, to gastric ulcer, chronic gastritis stomach
Bitterly, cancer of the esophagus has certain curative effect, and its dry product contains 17 kinds of amino acid, wherein have 7 kinds of essential amino acids for accounting for total amount 41.46%,
And 11 kinds of mineral matters and trace element, it is nutritious.The current research to HEIHUZHANG fungus both at home and abroad mainly concentrates enhancing immune
Power, antibacterial etc., but report is had no in the research of the application of anti-prostate cancer to HEIHUZHANG fungus extract.
The content of the invention
It is an object of the invention to provide HEIHUZHANG fungus extract in antiprostate cancer, health products or food is prepared
Application.
Preferably, the safe-dosaging limits of the HEIHUZHANG fungus extract are 10-500 mg/kg.
Preferably, the HEIHUZHANG fungus extract is the chloroform extract of HEIHUZHANG fungus.
Preferably, the preparation method of the chloroform extract of the HEIHUZHANG fungus comprises the following steps：
（1）By HEIHUZHANG fungus, coarse powder is ground into；
（2）HEIHUZHANG fungus coarse powder is loaded into leak device, adds 8 ~ 12 times of amount petroleum ethers, immersion 1-2 h；
（3）Take filter residue to add 8 ~ 12 times of amount chloroforms, soak 1-2 h, collect effusion, chloroform is recovered under reduced pressure, obtain the black tiger palm
The chloroform extract of bacterium.
Present invention also offers a kind of antiprostate cancer, includes HEIHUZHANG fungus extract and pharmaceutically acceptable load
Body.
The formulation of medicine of the present invention can be tablet, granule, pulvis, capsule or oral liquid etc., its preparation side
Method is prepared using conventional method.
The present invention compared with prior art, has the advantages that：
The present invention through vitro prostate cancer cells experimental studies have found that, HEIHUZHANG fungus extract can significantly inhibit prostate gland cancer cell
LNCaP, 22Rv1, PC-3 and DU-145 etc. growth；Interior animal experiment research simultaneously finds that HEIHUZHANG fungus extract can show
Write the growth for suppressing prostate gland cancer cell LNCaP transplanted tumor in nude mice；Confirmed through cell acute toxicity test, its safe-dosaging limits
It is larger, available for fields such as antiprostate cancer, health products or food.
Brief description of the drawings
Fig. 1 is optical microscope of the various concentrations HEIHUZHANG fungus extract to prostate cancer cell line LNCaP morphology influence
(100 times).
Fig. 2 is the column diagram of influence of the HEIHUZHANG fungus extract to LNCaP nude mice model tumor weights.
Embodiment
The present invention is further illustrated below by embodiment, following examples are the specific embodiment party of the present invention
Formula, but embodiments of the present invention are not limited by following embodiments.
HEIHUZHANG fungus of the present invention are bought in Kunming, Yunnan, and scientific name jujube Sarcodon imbricatus (L. Ex Franch.) Karst, cap is fleshy hypertrophy, fragrance
It is strong, it is canescence or taupe when fresh, becomes that dull gray is white or taupe after dry, shaped like brave pawl, lower surface covers with one layer of fibre
Thin canescence thorn-like fine hair, how hollow stem is sturdy, and long is somewhat inclined.
Embodiment 1：The preparation of HEIHUZHANG fungus extract
Specifically include following steps：
（1）By HEIHUZHANG fungus, coarse powder is ground into；
（2）HEIHUZHANG fungus coarse powder is loaded into leak device, 8 ~ 12 times of amount petroleum ethers is added, soaks 1-2h；
（3）Take filter residue to add 8 ~ 12 times of amount chloroforms, soak 1-2h, collect effusion, chloroform is recovered under reduced pressure, obtains HEIHUZHANG fungus
Chloroform extract.
By the chloroform extract of above-mentioned HEIHUZHANG fungus（CE）Carry out the test of pesticide effectiveness：
Test example one：Inhibitory activity of the chloroform extract of HEIHUZHANG fungus to prostate gland cancer cell multiplication capacity
Using the chloroform extract of the HEIHUZHANG fungus of various concentrations（25 μ g/mL, 50 μ g/mL, 100 μ g/mL）Act on normal
Prostate epithelial cell system（BPH）With 4 prostate cancers（LNCaP、22Rv1、PC-3、DU-145）Cell 48h, cell is collected,
Carry out cell counting kit-8（CCK-8 kits）The chloroform extract of proliferation experiment detection HEIHUZHANG fungus is to prostate
The proliferation inhibiting effect of cancer cell, as shown in table 1.Apply Cell Death Detection ELISA kit simultaneously（Cell withers
Die detection Enzymoimmune reagent kit）Influence of the chloroform extract of HEIHUZHANG fungus to apoptosis of prostatic carcinoma cell line is detected, such as Fig. 1 institutes
Show.
As can be seen from Table 1, the chloroform extract of HEIHUZHANG fungus suppresses cell growth in 5 all cell lines with dosage
The mode of dependence.With than normal prostatic epithelium cell line (BPH), 4 prostate cancer cell lines (LNCaP, 22 Rv1, PC-3,
DU-145 it is) more sensitive to the chloroform extract of HEIHUZHANG fungus.It is thin in 4 prostate cancers when administration concentration reaches 50 μ g/ml
In born of the same parents, its cell quantity is remarkably decreased, and is basically unchanged in BPH, is prompted the chloroform extract of HEIHUZHANG fungus to have and is suppressed forefront
The ability of adenocarcinoma cell propagation, and it is little to normal impact cell.
As seen from Figure 1, with the rise of chloroform extract concentration and the extension of action time of HEIHUZHANG fungus, tumour
Cell quantity is fewer and fewer, and the tumour cell quantity of Normal group then increases, and prompts the chloroform extract of HEIHUZHANG fungus to have
There is the ability for suppressing prostate gland cancer cell propagation.
Test example two：Inhibitory activity of the chloroform extract of HEIHUZHANG fungus to prostate cancer transplanted tumor in nude mice
LNCap nude mice models are established, orally give the chloroform extract of HEIHUZHANG fungus, animal items disease before and after being administered by observation
The index of correlation such as PSA (PSA) level, studies HEIHUZHANG fungus in shape, gross tumor volume, detection animal blood serum
The anti-prostate cancer activity of chloroform extract, and illustrate its possible mechanism of action.
2.1 modeling method
（1）The human prostata cancer LNCap cell lines in growth period of taking the logarithm are collected and are resuspended into serum free medium, make the concentration be
1.0×107cells/mL；
（2）40 nude mices adapt to environment 1 week, wherein 30（Experimental animal is several according to pertinent literature, into knurl time about 8-12
Week, modeling success rate 80% are counted）, the mL LNCap cell suspensions of subcutaneous vaccination 0.2 at omoplate, inoculum concentration be 1.0 ×
106Cells/ only, prepares animal model.Other 10 are Normal group.
2.2 experiment packets and administration
It is 250 mg/kg (CE- high doses group), 100 mg/kg (low dose of CE- by the chloroform extract dosage of HEIHUZHANG fungus
Amount group)；By daily single, successive administration 3 weeks.Model group and blank control group, which are given, isometric contains 0.5% carboxymethyl cellulose
The distilled water of plain sodium.
After modeling 3 weeks, with the maximum knurl footpath and most tubercle footpath of vernier caliper measurement nude mouse tumor mass, gross tumor volume is selected to fit
In nude mice 24, be randomly divided into 3 groups, every group 8；Separately add one group of Normal group（The normal nude mice of non-lotus knurl）, totally 4 groups.
Wherein packet and dosage regimen see the table below 2：
2.3 test indexes and observing time
（1）Use the method in measurement knurl footpath, the GVT of dynamic observation subject medicine.It is straight that the administration same day starts measurement tumour
Footpath, measure 1 time within every 2 days, observing time to experiment terminates（d21）；
（2）Every time mouse weight is weighed while measurement knurl footpath；
（3）Materials
Blood sample：After experiment terminates, pluck eyeball and take the mL of blood 1, after centrifugation, PSA in blood plasma is determined with Total PSA detection kits
Content；Relevant cell factor in blood plasma is detected with kit, the results are shown in Table 3.
Tissue：De- cervical vertebra puts to death mouse, and tumor bearing nude mice and tumor mass are photographed to record with digital camera, calculates tumor weight.
Shown in result figure 2.
Statistical method
Experimental data is with average value and standard deviation（±s）Represent, using the single factor test variance point in SPSS18.0 statistical softwares
Analysis carries out statistical test,p<0.05 expression difference has significant,p<0.01 represents that difference is anticipated with extremely conspicuousness
Justice.
As can be seen from Table 3, compared with normal group, each inflammatory factor of model group dramatically increases（P<0.05）；And gavage black
After the chloroform extract of Albatrellus dispansus (Lloyd) Canf. ＆ Gilb, each inflammatory parameters are remarkably decreased（P<0.05）, the chloroform extract of HEIHUZHANG fungus is prompted swollen
There is antiinflammatory action in knurl mouse.
As seen from Figure 2, compared with model group, after the chloroform extract for gavaging HEIHUZHANG fungus, the weight of its tumour shows
Writing reduces, wherein, model group（2.50.34）, CE- high dose groups（0.150.04）, CE- low dose groups（0.500.02）,
The chloroform extract of prompting HEIHUZHANG fungus can significantly inhibit the growth of prostate gland cancer cell LNCaP transplanted tumor in nude mice.
Safety evaluatio：
Toxicity test, according to《Chinese medicine, natural drug peace comment technological guidance's principle》, the dosage scope of HEIHUZHANG fungus extract is
10-500mg/kg.Maximum dosage-feeding 500mg/kg gavages give kunming mice, Continuous Observation 14 days, do not there is animal dead.Show
The safe-dosaging limits of HEIHUZHANG fungus extract are larger, drug safety.
Application examples：The preparation of capsule containing HEIHUZHANG fungus extract
Active ingredient：62 parts of the chloroform extract of HEIHUZHANG fungus；
Auxiliary material：28 parts of pregelatinized starch, 4 parts of superfine silica gel powder, 6 parts of magnesium stearate.
Preparation technology：By the chloroform extract of HEIHUZHANG fungus, pregelatinized starch, superfine silica gel powder, magnesium stearate input mixing
It is well mixed in machine.
Above-mentioned compound is packed into capsule by fully-automatic capsule filler, produced.
Claims (6)
1. application of the HEIHUZHANG fungus extract in antiprostate cancer, health products or food is prepared.
2. HEIHUZHANG fungus extract according to claim 1 is in antiprostate cancer, health products or food is prepared
Using, it is characterised in that the safe-dosaging limits of the HEIHUZHANG fungus extract are 10-500 mg/kg.
3. HEIHUZHANG fungus extract according to claim 1 is in antiprostate cancer, health products or food is prepared
Using, it is characterised in that the HEIHUZHANG fungus extract is the chloroform extract of HEIHUZHANG fungus.
4. HEIHUZHANG fungus extract according to claim 3 is in antiprostate cancer, health products or food is prepared
Using, it is characterised in that the preparation method of the chloroform extract of the HEIHUZHANG fungus comprises the following steps：
（1）By HEIHUZHANG fungus, coarse powder is ground into；
（2）HEIHUZHANG fungus coarse powder is loaded into leak device, adds 8 ~ 12 times of amount petroleum ethers, immersion 1-2 h；
（3）Take filter residue to add 8 ~ 12 times of amount chloroforms, soak 1-2 h, collect effusion, chloroform is recovered under reduced pressure, obtain the black tiger palm
The chloroform extract of bacterium.
5. a kind of antiprostate cancer, include HEIHUZHANG fungus extract and pharmaceutically acceptable carrier.
A kind of 6. antiprostate cancer according to claim 5, it is characterised in that the formulation of the medicine be tablet,
Granule, pulvis, capsule or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710352457.2A CN107412282B (en) | 2017-05-18 | 2017-05-18 | Application of ardisia nigripes extract in preparation of anti-prostate cancer drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710352457.2A CN107412282B (en) | 2017-05-18 | 2017-05-18 | Application of ardisia nigripes extract in preparation of anti-prostate cancer drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107412282A true CN107412282A (en) | 2017-12-01 |
| CN107412282B CN107412282B (en) | 2020-05-12 |
Family
ID=60425220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710352457.2A Expired - Fee Related CN107412282B (en) | 2017-05-18 | 2017-05-18 | Application of ardisia nigripes extract in preparation of anti-prostate cancer drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107412282B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109619247A (en) * | 2018-11-22 | 2019-04-16 | 安徽燕之坊食品有限公司 | It is a kind of with blood pressure lowering, blood lipid, the pressed candy of blood glucose and preparation method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53109916A (en) * | 1977-01-29 | 1978-09-26 | Kureha Chem Ind Co Ltd | Preparation of anti-tumor polysacaharides |
-
2017
- 2017-05-18 CN CN201710352457.2A patent/CN107412282B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53109916A (en) * | 1977-01-29 | 1978-09-26 | Kureha Chem Ind Co Ltd | Preparation of anti-tumor polysacaharides |
Non-Patent Citations (3)
| Title |
|---|
| 徐盼菊等: "黑虎掌菌化学成分及药理作用研究进展", 《山东医药》 * |
| 赵雨霁等: "翘鳞肉齿菌化学成分和药理活性研究概况", 《食用菌学报》 * |
| 陈健等: "黑虎掌菌多糖的组成和抗肿瘤活性", 《华南理工大学学报(自然科学版)》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109619247A (en) * | 2018-11-22 | 2019-04-16 | 安徽燕之坊食品有限公司 | It is a kind of with blood pressure lowering, blood lipid, the pressed candy of blood glucose and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107412282B (en) | 2020-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101366844B (en) | New use of loquat flower and its extract | |
| WO2013071727A1 (en) | Anti-tumor traditional chinese medical composition | |
| CN105169096A (en) | Medicine composition for treating gout or/and hyperuricemia | |
| CN105169105A (en) | Chinese medicinal preparation having functions of preventing tumors, nourishing yin and stomach and enhancing immunity and preparation method thereof | |
| CN111870609A (en) | Intestinal flora regulator and application thereof | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| CN109939153A (en) | A kind of anaesthetic for treating enteritis and preparation method thereof and preparation and preparation method | |
| Alburyhi et al. | Formulation, Development and Evaluation of Pandanus Odoratissimus Extract Capsules Delivery System as an Advanced Phytotherapy Approach for Hepatoprotective | |
| CN107412282A (en) | Application of the HEIHUZHANG fungus extract in antiprostate cancer, health products or food is prepared | |
| CN102389559B (en) | Traditional Chinese medicine composition and application as radiotherapy sensitizer | |
| CN103989695A (en) | Pharmaceutical composition for treating bronchial asthma and application thereof | |
| CN107308317B (en) | Traditional Chinese medicine composition for preventing and treating radiation damage | |
| Chuang et al. | Chinese Herbal Medicine Alleviates Thyroidectomy‐Induced Cardiopulmonary Exercise Dysfunction in Rats | |
| CN100360120C (en) | Application of fenugreek total alkali extract in preparing medicine for ulcerative colitis and preparation method of colon targeted preparation | |
| He et al. | Experimental study on the effect of a weifufang on human gastric adenocarcinoma cell line BGC-823 xenografts and PTEN gene expression in nude mice | |
| Sun et al. | Combined exploration of the mechanism of Sang Xing Decoction in the treatment of smoke-induced acute bronchitis from protein and metabolic levels | |
| CN103463253B (en) | Fungus medicament for preventing postoperative cancer recurrence and production method thereof | |
| CN106806376A (en) | The pharmaceutical composition of paracetamol and glycyrrhizic acid or its salt or derivatives thereof | |
| CN102423384A (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN104587017B (en) | A kind of Clearing heat and removing obstruction of fu-organs, pharmaceutical composition of the promoting flow of qi and blood circulation and its production and use | |
| CN108704036A (en) | A kind of Chinese traditional compound medicine and preparation method thereof for treating gout | |
| CN111671795B (en) | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy, traditional Chinese medicine preparation and application | |
| CN107252444A (en) | It is a kind of to be used to treat and/or prevent herbal composite of prostatic disorders and its preparation method and application | |
| CN108066397A (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200512 |